Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Renalytix shares jump on draft US Medicare coverage decision

(Sharecast News) - Renalytix shares were rocketing on Friday morning, after it announced that the Centers for Medicare and Medicaid Services (CMS) in the US had published a draft local coverage determination (LCD) for its 'KidneyIntelX' and 'kidneyintelX.dkd' testing products, outlining the coverage and pricing for the tests. The AIM-traded firm said that according to the draft LCD, the established Medicare price for KidneyIntelX and kidneyintelX.dkd would be $950 per test.

Distinct common procedural terminology (CPT) codes, used in the US healthcare system for common billing across providers, had been set for each test and were available in the CMS 2024 clinical lab fee schedule.

The company said the draft LCD specified coverage for the use of KidneyIntelX or kidneyintelX.dkd for patients with diagnosed type-2 diabetes and stage 1 to 3b chronic kidney disease as reasonable and necessary.

Any limitations specified in the draft LCD aligned with the US Food and Drug Administration (FDA) label for kidneyintelX.dkd, it noted.

National Government Services (NGS), a subsidiary of Elevance Health, submitted the LCD.

NGS serves as a Medicare administrative contractor with CMS, responsible for claim review and payment for testing conducted in Renalytix's New York City laboratory.

A 45-day public comment period started on 8 February, and would end on 23 March.

Renalytix formally requested an LCD from NGS and provided substantial peer-reviewed published evidence supporting the coverage of KidneyIntelX and kidneyintelX.dkd.

NGS conducted a contractor advisory committee meeting on 29 August 2023, where a panel of external experts reviewed and discussed the clinical evidence.

Renalytix said it believed that, based on that evidence and the FDA's de Novo marketing authorisation for the kidneyintelX.dkd test, there was a strong basis for NGS to determine the tests as reasonable and necessary for Medicare beneficiaries.

Following the open public meeting, NGS would review public comments and issue a final LCD, expected within 2024.

At 1012 GMT, shares in Renalytix were up 30.54% at 13.38p.

Reporting by Josh White for

Share this article

Related Sharecast Articles

SigmaRoc delivers 'solid' Q1 performance
(Sharecast News) - Limestone group SigmaRoc said on Friday that it had delivered a "solid Q1 performance", with underlying earnings in line with management expectations.
Samsung in line to secure $6bn in US government grants
(Sharecast News) - Electronics giant Samsung will unveil a $44.0bn White House programme aimed at bringing semiconductor production back to America as soon as next week, with the memory chip maker in line to secure up to $6.0bn in government grants.
BAE Systems 'still riding high', says Deutsche Bank
(Sharecast News) - Deutsche Bank has hiked its target price for BAE Systems and maintained a 'buy' rating on the aerospace and defence stock, saying that recent growth momentum is likely to continue.
Societe Generale sells Moroccan unit to Saham Group
(Sharecast News) - French bank Societe Generale has agreed to sell the majority of its Moroccan arm to Saham Group for €745.0m as it forges ahead with chief executive Slawomir Krupa's plan to streamline the business.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.